Hypothesis: Can neuroendocrine immune (NEI) testing of individual RA patients guide benefits to harms ratio in glucocorticoid therapy?

We compliment and endorse the "Official View" by Palmowsky Y and the multidisciplinary experts on their review of guidelines for glucocorticoid (GC) therapy in rheumatoid arthritis (RA) (1). The guidelines generally agreed that GCs are an appropriate option for RA therapy, especially at low doses and for a short duration (1). However, the recommendations lacked evidence and guidance on doses, timing, and duration of GC use. Authors concluded that high-quality studies of GCs in RA are urgently needed (1). This article is protected by copyright. All rights reserved.